A phase 1/2 study of MT‐3724 to evaluate safety, pharmacodynamics and efficacy of MT‐3724 for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma Meeting Abstract
| Authors: | Burnett, C. A.; Hamlin, P.; Dabovic, K.; Higgins, J.; Persky, D. O. |
| Abstract Title: | A phase 1/2 study of MT‐3724 to evaluate safety, pharmacodynamics and efficacy of MT‐3724 for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma |
| Meeting Title: | 15th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 37 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2019 Jun 18-22 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2019-06-01 |
| Start Page: | 566 |
| Language: | English |
| ACCESSION: | 136932447 |
| DOI: | 10.1002/hon.13_2632 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| PUBMED: | 31187525 |
| DOI/URL: | |
| Notes: | Meeting abstract: OT20 -- Accession Number: 136932447 -- Entry Date: In Process -- Revision Date: 20190617 -- Publication Type: Article -- Supplement Title: Jun2019 Supplement S1 -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20 |
